Dr. Rami Komrokji, MD
Claim this profileMoffitt Cancer Center
Studies Myelodysplastic Syndrome
Studies Preleukemia
14 reported clinical trials
19 drugs studied
Area of expertise
1Myelodysplastic Syndrome
SRSF2 positive
SF3B1 positive
U2AF1 positive
2Preleukemia
Hgb
SF3B1 positive
ZRSR2 positive
Affiliated Hospitals
Clinical Trials Rami Komrokji, MD is currently running
Canakinumab + Darbepoetin Alfa
for Myelodysplastic Syndrome
This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)
Recruiting1 award Phase 1 & 26 criteria
Discontinuing Decitabine/Azacitidine + Venetoclax
for AML
The purpose of this research study is to see if people whose Acute myeloid leukemia (AML) is being successfully treated with azacitidine or decitabine in combination with venetoclax can discontinue this chemotherapy for some period of time after a year of treatment without increasing the likelihood that their AML will return.
Recruiting1 award Phase 26 criteria
More about Rami Komrokji, MD
Clinical Trial Related3 years of experience running clinical trials · Led 14 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Rami Komrokji, MD has experience with
- Luspatercept
- Epoetin Alfa
- Oral Azacitidine
- Placebo For Oral Azacitidine
- Lenalidomide
- Epoetin Alfa
Breakdown of trials Rami Komrokji, MD has run
Myelodysplastic Syndrome
Preleukemia
Syndrome
Leukemia
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Rami Komrokji, MD specialize in?
Rami Komrokji, MD focuses on Myelodysplastic Syndrome and Preleukemia. In particular, much of their work with Myelodysplastic Syndrome has involved SRSF2 positive patients, or patients who are SF3B1 positive.
Is Rami Komrokji, MD currently recruiting for clinical trials?
Yes, Rami Komrokji, MD is currently recruiting for 6 clinical trials in Tampa Florida. If you're interested in participating, you should apply.
Are there any treatments that Rami Komrokji, MD has studied deeply?
Yes, Rami Komrokji, MD has studied treatments such as Luspatercept, Epoetin Alfa, Oral Azacitidine.
What is the best way to schedule an appointment with Rami Komrokji, MD?
Apply for one of the trials that Rami Komrokji, MD is conducting.
What is the office address of Rami Komrokji, MD?
The office of Rami Komrokji, MD is located at: Moffitt Cancer Center, Tampa, Florida 33612 United States. This is the address for their practice at the Moffitt Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.